Dermatological Side Effects of Targeted Antineoplastic Therapies: A Prospective Study.

The objective of this study is to report the cutaneous side effects of EGFR inhibitors and to share treatment methods for such side effects.Materials and method: In this prospective study, 59 patients using EGFR due to breast and colorectal carcinoma at the oncology unit of Haseki Training and Research hospital were assessed. The patients for whom EGFR was initiated were examined at the beginning of the treatment at weeks 1 and 2, their demographic characteristics were recorded, and the patients who developed a skin rash were followed up from the onset of the lesion. The papulopustular side effects that developed in the patients and other dermatological findings were recorded. The papulopustular side effects were graded, and the treatment plans were reported. The study was conducted between February 2016 and February 2018 under the approval of the local ethical committee.Results: The mean age of the 59 patients (47 females, 12 males) taking EGFR inhibitors was 52.4 ± 12.0 (range: 29-84). Forty-five patients had early stage and 14 patients had advanced stage carcinoma. Fourteen patients had colorectal carcinoma, 3 patients had renal cancer, and 42 patients had breast cancer. Forty-two patients were using trastuzumab (single therapy in 29 patients and combined therapy in 13 patients), 5 patients were using cetuximab, 3 patients were using sunitinib, 8 patients were using panitumumab, and 6 patients were using pertuzumab. In 22 patients, papulopustular side effects were obs...
Source: Cutaneous and Ocular Toxicology - Category: Toxicology Authors: Tags: Cutan Ocul Toxicol Source Type: research